Phase 3
Completed N=1,036
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Post Operative Surgical Site Infection
Source: ClinicalTrials.gov NCT02227446 ↗
Enrolled (actual)
1,036
Serious AEs
3.8%
Results posted
Jun 2021
Primary outcomePrimary: Number of Clinically Significant Deep Surgical Site Infection (SSI) — 29; 48; 1; 1 surgical site infections
◆ Published Evidence
Highly cited
121citations · ~24 / year
Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial.
Summary
The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixation.
Linked Publications (2)
-
Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial.
-
Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Clinically Significant Deep Surgical Site Infection (SSI) |
29; 48; 1; 1; 17; 36 | — |
| SECONDARY Bacterial Antibiotic Resistance Rate of Infected Participants |
— | — |
| SECONDARY Identify Risk Factors for Infection |
— | — |
Eligibility Criteria
Inclusion Criteria
- All "high energy" tibial plateau fractures treated operatively with plate and screw fixation.
- We define "high energy" tibial plateau fractures as patients who are either:
- Initially treated with an external fixation (with or without limited internal fixation) and treated definitively more than 3 days later after swelling has resolved.
- Any open type I, II, or IIIA fracture, regardless of timing of definitive treatment.
- Any tibial plateau fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds.
- All "high energy" pilon (distal tibial plafond) fractures treated operatively with plate and screw fixation. We define "high energy" pilon fractures as patients who are either:
- Initially treated with an external fixation (with or without fibula fixation or limited internal fixation) and treated definitively more than 3 days later after swelling has resolved.
- Any open type I, II, or IIIA fracture, regardless of timing of definitive treatment.
- Any tibial pilon fracture associated with ipsilateral leg compartment syndrome fasciotomy wounds.
- Ages 18 to 80 years
- Patients may have co-existing non-tibial infection, with or without antibiotic treatment.
- Patients may have risk factors for infection including diabetes, immunosuppression from steroids or other medications, HIV, or other infections.
- Patients may have a head injury
- Patients may have a portion of the fixation (e.g. fibula fixation in pilon or percutaneous screws across a tibial plateau fracture) prior to definitive plate fixation, at the initial surgery before randomization.
- Patients may have other orthopedic and non-orthopaedic injuries.
- Patients may have pre-existing musculoskeletal injuries, be non ambulators, or have spinal cord injuries.
- Women and minorities are included
Exclusion Criteria
- The study injury: tibial plateau, pilon, is already infected at time of study enrollment.
- Patient speaks neither English nor Spanish.
- Patients who have already had definitive fixation prior to enrollment in the study.
- Severe problems with maintaining follow-up (e.g. patients who are homeless at the time of injury or those how are intellectually challenged without adequate family support).
- Patients with allergies, drug administration reactions, or other sensitivities to Vancomycin (such as a history of Redman's Syndrome).
- Pregnancy.
- The study injury is a type IIIB or IIIC open fracture.
Data sourced from ClinicalTrials.gov (NCT02227446) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.